This study aims to examine prescribing patterns of COPD medications, adherence to The Global Initiative for Chronic Obstructive Lung Disease ( GOLD) 2013 guideline, and impact of the adherence on clinical and economic outcomes. A retrospective study was conducted at Ramathibodi hospital. All COPD patients receiving treatment during July 1-December 31, 2012 were identified from electronic database. Index date was determined as the first date with FEV1 during the recruitment period. Data on treatment, cost, and clinical outcomes were reviewed for 1 year after index date. The results were included 109 patients. 84 patients ( 77. 06%) and 25 patients ( 22. 94%) were classified into group 1 ( FEV1 ≥ 50%) and group 2 ( FEV1 < 50%), respectively. It was found that group 1 reported significantly lower exacerbation rate ( 26. 19% vs 80. 00%) than group 2. SABA/ SAMA was the most prescribed drugs (97.61% in group 1 and 100% in group 2). Overtreated with ICS was common (63.09%) with FEV1 ≥ 50%.
INTRODUCTION
Chronic Obstructive Pulmonary Disease ( COPD) , characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/ or alveolar abnormalities, is recognized as an important public health concerns globally. In 2015, approximately 3.17 million deaths or approximately 5% of all death globally was caused by COPD 1 . In high-income countries, COPD was the fifth leading cause of death while it ranked the sixth leading cause of death in low and middle-income countries 2 . Furthermore, the burden from COPD was projected to increase. It was estimated that COPD will be the fourth leading causes of death by 2030 3 .
COPD imposed significant economic burden. The annual direct expenditures for COPD treatment per patient in Europe and North America ranged US$ 520 in France to US$ 4,120 in the US ( 2002 value) 4 . According to the review, most direct costs were incurred from hospitalizations 4 . In addition, indirect costs of COPD due to sick leaves,restricted activity day and disability day were substantial with the estimated annual indirect cost of US$ 1,521-US$ 3,348 per patient ( 2010 value) . In the studies that assessed both direct and indirect cost, it was found that indirect costs accounted for 27%-61% of total costs 5 .
Since 1997, the Global Initiative for chronic obstructive lung disease ( GOLD) was established to raise awareness of COPD and to improve prevention and treatment of this disease. According to the 2009 GOLD criteria, severity of COPD patients with an FEV1/ FVC < 0. 70 was classified based on post bronchodilator lung function into 4 groups as follows; 1. GOLD 1 ( mild): FEV1 ≥ 80% predicted; 2. GOLD 2(moderate): 80% > FEV1 ≥ 50%; 3. GOLD 3 (severe): 50% > FEV1 ≥ 30%; and 4. GOLD 4 (very severe): 80% > FEV1 < 50%. Later in 2011, the " ABCD" assessment tool that incorporated patient reported outcome and highlighted the importance of exacerbations was proposed. In the " ABCD" assessment scheme, patients are required to undergo spirometry, either assessment of dyspnea using Modified Medical Research Council dyspnea scale ( mMRC) or symptoms using COPD Assessment Test (CAT). In addition, patient' s history of exacerbations was taken into account.
According to GOLD 2014, short-acting bronchodilator medication either short-acting muscarinic agonist ( SAMA) or short-acting β2agonists ( SABA) are recommended for immediate relief from symptoms while one or more long-acting including long-acting β2agonists ( LABA) or long-acting muscarinic antagonist ( LAMA) are recommended for long term maintenance therapy in patients with moderate to severe COPD. Inhaled corticosteroid ( ICS) is recommended in addition to a maintenance treatment with a LABA and/ or LABA+ LAMA for patients with severe or very severe air flow limitations and/ or 3 or more exacerbations per year 7, 8 . Similar to GOLD, NICE guidelines also recommended ICS in addition to a LABA for patient with severe airflow limitation (FEV1 < 50%) and recurrence exacerbations and/ or breathless 6 .
Evidences from several countries indicated that the adherence to GOLD recommendations was suboptimal [7] [8] [9] [10] [11] [12] [13] . Overtreatment especially among mild and moderate COPD was commonly observed 9-10,12 . While existing evidence indicated that the use of ICS has been associated with increased risk of pneumonia [14] [15] , a significant proportion of mild and moderate COPD patients being treated with ICS was reported in several studies 7, 9, 11 . On the other hand, under-treatment was also identified 8, 11 .
Besides the low adherence to GOLD guideline, the impact of adherence to such guideline on clinical outcomes of COPD and cost of treatment was limited and unclear. Previous study 10 found that there was no relationship between adherence and exacerbation while the recent study 8 identified inverse relationship between non-adherence and exacerbation. One study reported the lower cost among the adherence group compared to non-adherence group 16 .
In Thailand, according to the Bureau of epidemiology, Department of disease control, prevalence of COPD was estimated at 176.77 per 100,000 populations in 2013. COPD ranked the fifth leading cause of DALY loss among Thai male in 2009 17 . Age-adjusted deaths from COPD in Thailand was estimated at 48. 0 per 100,000 2 . The average cost per patient per year ranged from 6,084 baht for mild to 16,527 baht for very severe patient (2015 value, 30 baht = $1) 18 . The majority of direct costs were incurred in out-patient care 18 . Very little is known about the prescribing patterns of COPD treatment in upper-middleincome countries including Thailand. Thus, the objectives of this study were to examine the prescribing patterns and COPD treatment expenditure at one university hospital in Thailand. In addition, we aim to examine whether treatments were in line with GOLD 2013 guideline and to determine the impact of adherence to the guideline on clinical outcomes and cost of treatments.
METHODS

Study design and participants
This study is a retrospective study conducting at Ramathibodi hospital, a 1000-bed teaching hospital in Bangkok.
Participants
Participants were all COPD patients receiving care during July 1-December 31, 2012. Participants were identified from electronic database using International Classification of Diseases and Related Health Problem, Tenth Revision (ICD-10) codes (J44). 
Sample and sample size calculation
The total number of COPD patients included in this study ( n) was calculated using following equation: n = 1−∝/2 2 * P (1-P)/ M 2, 19 . As there was no previous data on prevalence of adherence to GOLD guideline in Thailand ( P) before, then P was set at 0. 5 19 . By using type 1 error (α) at 0.05 and setting margin of error (M) at 10% , the required sample size was estimated at 100. Patients were excluded if they had no information on post bronchodilator FEV1/ FVC ratio and the FEV1 on their medical records or had incomplete medical record.
With the assumption that approximately 15% of COPD patients had information on post bronchodilator FEV1/ FVC ratio and the FEV1 on their medical records and that the total number of COPD patients identified from electronic database during the recruitment period were approximately 1,600, 50% of all identified COPD patients (800) were randomly selected.
Then, their medical records were reviewed to determine the eligibility. Index date was determined as the first date with post bronchodilator FEV1 during the recruitment period.
Data collection
The study was approved by the Human Research Ethics Committee of Ramathibodi hospital in 2014. For each eligible patient, data on treatment, cost, and clinical outcomes were reviewed for 1 year after index date. The following data were collected from electronic medical recording; age, gender, type of insurance, pharmacological treatments, number of outpatient visits, admission data, number of exacerbation, and number of emergency room visits. Treatment expenditure, which included charges of drug, X-ray, and other services incurred from outpatient visit emergency room visit and hospitalization, were also collected from electronic database. 
Data analysis
Each eligible patient was classified into 2 groups as group 1 (FEV1 ≥ 50%) and group 2 (FEV1 < 50%). Pattern of treatments was reported in terms of descriptive statistics. Patients were then classified as receiving appropriate and inappropriate (i.e. over-treated, under-treated) treatments based on GOLD recommendations, as shown in Table 1 . If patients were prescribed medications that were recommended for a more severe stage than their own classification they were classified as being over-treated. On the other hand, if they were prescribed treatment based upon the severity category less severe than their own severity stage they were considered as under-treated. Comparison of clinical outcomes such as number of exacerbations, number of hospitalizations, number of ER visits, and cost was conducted by independent t-test. Mann-Whitney U test was used if data were not normally distributed. Level of significant difference was set at p-value < 0.05. Annual treatment expenditure per capita per year was also calculated for each group of patients.
RESULTS
Of the total 1,608 COPD patients identified from the electronic database, 804 (50%) were randomly selected. Only 109 patients who had information on post bronchodilator FEV1/ FVC ratio and the FEV1 and had complete medical record were included in the study. Then, 84 patients (77.1%) were classified into group 1 (FEV1 ≥ 50%) while 25 patients (22.9%) were classified into group 2 ( FEV1 < 50% ) . Characteristics of included patients were summarized in Table 2 . The mean FEV1 in group 1 was 72. 5% , while that of group 2 was 34. 8% . There was no significant difference between the two groups in terms of age, gender, co-morbidity and health insurance coverage. 
Clinical outcomes
Clinical outcomes and resource utilizations were shown in Table 3 . COPD patients in group 1 reported significantly lower exacerbation rate (26.19%) than patients in group 2 (80.00%). The mean frequency of exacerbation in past year was also lower in group 1 ( 1. 27 VS 2.47). None of them were death during the study period. In terms of resource utilizations, there was no significant difference between group 1 and group 2 in terms of number of patients visiting to ER as well as number of ER visit, as shown in Table 3 .
Prescribing patterns
Details on medication treatments of the patients were displayed in Table 4 . Average number of drug items prescribed among patients with poor lung function ( group 2) was higher than that of patients with well-preserved lung function ( group 1) approximately two times. However, significant difference was not observed. In terms of prescribing patterns, SABA-SAMA were prescribed in 97. 61% of group 1 and 100. 00% of group 2. ICS+ LABA combinations ( fluticasone/ salmeterol and budesonide/ formoterol) were prescribed in 60. 71% of group 1 and 96. 00% of group 2 patients. LABA ( indacaterol and bambuterol) was prescribed in 5. 95% , and 4. 00% of group 1 and group 2, respectively. LAMA was prescribed in 30. 95% and 56. 00% in group 1 and group 2, respectively. When comparing between group 1 and group 2, it was found that LAMA and ICS+ LABA ( fluticasone/ salmeterol) were significantly prescribed in group 2 more than group 1.
When focused on comparison of appropriateness of COPD medications based on GOLD 2013 guideline in Table 5 , for group 1 patients, 28.60% of patients receive appropriate treatment while approximately 69.00% and 2.40% were considered over-treated and undertreated, respectively. On the other hand, 96.00% of patients with post bronchodilator FEV1< 50% (group 2) received appropriate while 4.00% (n =1) were under-treated.
Economic outcomes
As shown in Table 6 , for group 1 patients, average annual treatment expenditure per capita was US$ 411. Drug was the major part of the total expenditures (71.23%). It was found that cost incurred in OPD was the highest (90.74%). For group 2 patients, average annual treatment expenditure per capita was US$ 703. Similar to group 1 patients, drug was the major part of the total expenditure and cost incurred in OPD was the highest.
Impact of adherence to GOLD 2013 guideline
When considered patients in group 1, as shown in Table 7 , there was no significant difference between patients with appropriate treatment and inappropriate treatment in terms of clinical outcomes, resource utilizations (i.e. proportions of patients reported having exacerbation, number of exacerbations, proportion of patients reported having ER visit, number of ER visits, proportion of patient reported have been hospitalized, number of hospitalizations, and length of stay), and annual expenditure per capita. On the other hand, almost all of patients in group 2 (96.00%) received appropriate treatment. Therefore, comparison of clinical outcomes between patients with appropriate treatment and inappropriate treatment was not conducted.
DISCUSSION
Due to the lack of information on mMRC and CAT, we categorized patients only from FEV1. In our study, however, more than half of COPD did not completely undergo spirometry and were excluded from the study, so we classified patients into only 2 groups as having FEV1 ≥ 50% (group 1) and FEV1 < 50% (group 2). Although our criterion was slightly different than GOLD, we confirmed that COPD patients in group 2 reported significantly higher exacerbation than group 1. This confirmed that, in case of limited data on mMRC and CAT, FEV1 alone was an acceptable criteria to classify COPD severity.
When looking at treatment patterns, SABA-SAMA was the most prescribed drugs ( 97. 61% in group 1 and 100. 00% in group 2) . ICS+LABA was the second most prescribed drug and was prescribed to 60. 71% of patients with post bronchodilator FEV1 ≥ 50%. Our findings were similar to those of previous studies 9-12 . Jochmann et al found that ICS+ LABA regimen was the most prescribed drug ( 60% of all patients) . Price et al found that ICS+ LABA and ICS+ LABA+ LAMA were the most frequently used treatments in well-preserved lung function (49.9% in group A & 46.6% in group B). Gunen et al found LABA+ LAMA+ ICS regimen was noted in 62% of mild to moderate lung function.
In line with many previous studies which found that adherence to treatment guideline is suboptimal ranking from 19% 8 to 60% 12 and that overuse of ICS among patient with mild and moderate COPD was common 7-9,11-12 , we found that only 44% of COPD patients received appropriate treatment (28.60% for group 1 and 96.00% for group 2). In our study, over-treated with ICS was high (69.00%) among patients with mild and moderate COPD (group 1). As patients with mild and moderate COPD had lower risk of exacerbation, over treatment medications with ICS were not appropriate and might be associated with pneumonia [14] [15] . However, we did not collect data about adverse effects of ICS overuse in terms of pneumonia in this study.
There are several reasons for overuse of ICS in mild and moderate COPD. First, it might be due to the unfamiliar with the treatment guidelines and the concern of physicians regarding the exacerbation. Previous study 7 found that previous exacerbation was a strong predictor associated with prescribed ICS or ICS combination in mild to moderate lung function patients. Furthermore, the other possible reason was related to the health insurance issue. In Thailand, all ICS or ICS combination were listed in essential drug list and then can be reimbursed. On the other hand, only some LABA can be reimbursed. While the price of LAMA was higher than those of ICS or ICS+LABA, LAMA was not in the essential drug list and cannot be reimbursed by the public insurance scheme. These above issues can help explaining why LAMA and LABA were less frequently used than ICS and ICS combination among mild and moderate COPD patients.
Among COPD patients with wellpreserved lung functions (group 1), clinical outcomes and resource utilizations between patients receiving appropriate medications and inappropriate medications was not found to be significantly different. Our findings were in accordant with the result of previous study 10 which found no statistically significant difference between adherence and non-adherence groups in term of exacerbation year but in contrasted with recent study 8 that found inverse relationship between under-treated and exacerbation. The possible reason of non-significant impact of adherence to guideline found in our study and previous study 10 was probably due to the short duration of study.
In terms of treatment expenditures, in contrast to previous study 16 we found no significant difference between patients receiving appropriate and inappropriate treatment. This probably due to the fact that our duration of study was too short (1 year) so no significant difference in terms of clinical outcome was identified and that most inappropriate treatment in our study was overuse of ICS, which is not expensive. In contrast to other previous studies [20] [21] [22] , all conducted in western countries, which found that inpatients hospitalization was the largest proportion of the overall direct cost, we found that drug expenditures incurred in outpatient department accounted for the largest part of total expenditures.
In our study, average annual treatment expenditure per capita was US$ 411 for group 1 and US$ 703 for group 2. Nevertheless, it should be noted that these figures were tend to be underestimated as the expenditure was calculated from electronic database from Ramathibodi hospital only. It might be the case that patients had ER visits or had been hospitalized at other hospitals or purchased other COPD drugs from the drugstores. In addition, indirect cost such as caregiver cost, cost of absenteeism was not included. Thus, the true annual cost of COPD treatments may be higher than reported in this study.
There are some limitations of this study that should be acknowledged. First, due to retrospective design using electronic database, some clinical and medical histories of a patient might be missing or inaccurate due to miscoding. Nevertheless, there are many advantages of using electronic database. For example, the use of database consumed less resources in terms of cost and time, providing the opportunity for routine monitoring of drug treatment. Recently, many pharmacoepidemiology studies were conducted using hospital database [23] [24] [25] [26] . Other limitation was that the number of eligible patients were limited as pulmonary lung function test with spirometry in COPD was not routine investigated in realpractice in many upper-middle-income countries including Thailand. As the result, many patients were excluded from the study. Another limitation was that follow up period symptoms of patient after index date was too short time (1 year). Long-term study (> 1.5 years) should be further conducted to examine the impact of overuse of ICS [27] [28] [29] [30] . It should also be noted that our study was conducted in only one hospital with limited number of patients especially those with FEV1 < 50, therefore, generalizability of our findings should be made with caution.
As the number of studies examining impact of adherence to GOLD guideline on clinical outcomes and treatment expenditures are limited and also inconclusive, to promote the adherence to GOLD 2013 guideline, further longterm and with larger number of patients from several hospitals are clearly needed. In addition, the dosage of treatment should also be taken into account in the analysis.
CONCLUSIONS
Our study indicated that adherence to GOLD 2013 guideline was sub-optimal. Adherence to GOLD 2013 guideline was higher in severe group (group 2) than in mild and moderate group (group 1). Over-treated with ICS was common (63.09%) among patients with FEV1 ≥ 50%. On the other hand, appropriate-treated was found almost 100% in severe group. SABA-SAMA was the most prescribed medicine in both groups. Nevertheless, no association between adherence to GOLD 2013 guidelines and clinical or economic outcomes was found among COPD patients.
Medication expenditures was the highest cost of total hospital expenditures in both groups. Majority of cost was incurred in outpatient service. Although the annual expenditure per capita was found to be higher in group 2 (US$ 703) than group 1 (US$ 411), no statistically significant difference was found. Nevertheless, due to the small sample size and short follow up duration, it was premature to conclude that adherence to GOLD guideline had no impact on clinical outcomes and economic outcomes. To promote the adherence to GOLD 2013 guideline, further long term studies conducted in large number COPD patients on the impact of adherence to GOLD guideline on clinical, economic, and humanistic outcomes are clearly needed.
